News coverage about Kamada (NASDAQ:KMDA) has trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Kamada earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.6323149336906 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Kamada (NASDAQ KMDA) remained flat at $$4.55 during trading on Friday. The company had a trading volume of 972 shares, compared to its average volume of 24,505. Kamada has a twelve month low of $3.75 and a twelve month high of $8.61. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.71 and a quick ratio of 2.73.
Several equities research analysts recently commented on the company. ValuEngine cut Kamada from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research raised Kamada from a “sell” rating to a “hold” rating in a report on Tuesday, August 15th. Finally, Jefferies Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Kamada in a research report on Thursday, October 12th. Two analysts have rated the stock with a sell rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $8.50.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.